<DOC>
	<DOCNO>NCT00836498</DOCNO>
	<brief_summary>This Phase I clinical trial include 2 part evaluate safety immune response RotaTeq™ /placebo subject 65 80 year age . In Part I , approximately 60 subject US randomly assign 1 2 treatment group receive 3 dos RotaTeq™ placebo . In Part II , approximately 200 subject internationally randomly assign 1 3 treatment group . Part II start Part I data analysis review approved FDA/CBER , Safety Evaluation Committee ( SEC ) regulatory agency . Duration entire study approximately 4 year . Note : As result business decision Sponsor , study proceed Part II . Therefore , report include result Part I .</brief_summary>
	<brief_title>A Study Safety Immune Response RotaTeq™ Vaccine Elderly ( V260-027 )</brief_title>
	<detailed_description />
	<criteria>Is 65 80 year age control chronic illness agree participate study give write informed consent cognitively competent assess MiniMental State Examination Part I : subject live independently outside longterm care facility ; Part II : subject expect resident long term care facility ( LTCF ) include nurse home exception hospice care adequately follow safety via visit phone subject 's routine safety lab result within specified range negative test result HIV , Hepatitis B , Hepatitis C abdominal cancer/surgery within past 6 month know suspected immune disease , e.g . diabetes chronic relapse infection fever time immunization active vomit diarrhea time immunization chronic diarrhea , irritable bowel syndrome , inflammatory disease intestinal colon past 12 month subject ' spouses/cohabitants healthy immunocompromised ; roommate LTCFs healthy and/or agree participate study adequately follow safety via visit phone clinically significant condition , investigator ' opinion , would interfere subject 's participation study</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>